<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05125848</url>
  </required_header>
  <id_info>
    <org_study_id>ZMS-1500-2021-Dialysis</org_study_id>
    <nct_id>NCT05125848</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the CM-1500 During Hemodialysis</brief_title>
  <official_title>Clinical Evaluation of the CM-1500 During Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zynex Monitoring Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zynex Monitoring Solutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective, single-arm, non-randomized, non-blinded, non-controlled,&#xD;
      non-significant risk, single center study enrolling up to 20 subjects consented to undergo a&#xD;
      hemodialysis session as a part of their standard prescribed treatment plan. Subjects will&#xD;
      consent to undergo non-invasive monitoring with the CM-1500 during three (3) separate&#xD;
      sequential hemodialysis sessions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 16, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize changes in the Relative Index During a Hemodialysis Procedure</measure>
    <time_frame>1-6 hours</time_frame>
    <description>The primary objective of the study is to characterize changes in the CM-1500 Relative Index over the duration of a hemodialysis procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the intersubject and intrasubject variability in Relative Index changes across multiple hemodialysis sessions</measure>
    <time_frame>1-2 weeks</time_frame>
    <description>The secondary objective of the study is to characterize the intersubject and intrasubject variability in Relative Index changes across the three hemodialysis sessions</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Fluid Loss</condition>
  <condition>Dialysis</condition>
  <arm_group>
    <arm_group_label>Hemodialysis Single Group Assignment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CM-1500</intervention_name>
    <description>The CM-1500 is a U.S. FDA cleared non-invasive monitoring device that simultaneously monitors five (5) parameters of a patient's body. A combination of these parameters is represented by a single number known as the Relative Index value. This value is indicative of relative changes in fluid volume.</description>
    <arm_group_label>Hemodialysis Single Group Assignment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to provide written informed consent&#xD;
&#xD;
          -  Ability and willingness to comply with the study procedures and duration requirements,&#xD;
             including connection of the device to the left wrist/hand and maintaining relatively&#xD;
             motionless during the session&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Planned to undergo a minimum of three (3) hemodialysis sessions within the two (2)&#xD;
             weeks following enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding&#xD;
&#xD;
          -  Undergone an amputation of the left upper extremity&#xD;
&#xD;
          -  Subjects with left arm hemodialysis access only&#xD;
&#xD;
          -  Diagnosed with dextrocardia&#xD;
&#xD;
          -  Subjects who have a pacemaker&#xD;
&#xD;
          -  Subjects who have any other underlying condition that would inhibit completion of&#xD;
             participation in the study, per Investigator opinion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Tolins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>InterMed Consultants</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Seiberlich, MS</last_name>
    <phone>6512040567</phone>
    <email>lseiberlich@zynex.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Donald Gregg</last_name>
    <phone>800-495-6670</phone>
    <phone_ext>3802</phone_ext>
    <email>dgregg@zynex.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Christine Majeski, RN, CCRC</last_name>
      <phone>612-852-7027</phone>
      <email>christine.majeski@davita.com</email>
    </contact>
    <investigator>
      <last_name>Jonathan Tolins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Connaire, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 8, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

